1. Academic Validation
  2. Mechanism of Differential Susceptibility of Two (Canine Lung Adenocarcinoma) Cell Lines to 5-Aminolevulinic Acid-Mediated Photodynamic Therapy

Mechanism of Differential Susceptibility of Two (Canine Lung Adenocarcinoma) Cell Lines to 5-Aminolevulinic Acid-Mediated Photodynamic Therapy

  • Cancers (Basel). 2021 Aug 19;13(16):4174. doi: 10.3390/cancers13164174.
Tomohiro Osaki 1 Narumi Kunisue 2 Urara Ota 2 Hideo Imazato 2 Takuya Ishii 2 Kiwamu Takahashi 2 Masahiro Ishizuka 2 Tohru Tanaka 3 Yoshiharu Okamoto 1
Affiliations

Affiliations

  • 1 Joint Department of Veterinary Clinical Medicine, Faculty of Agriculture, Tottori University, Tottori 680-8553, Japan.
  • 2 SBI Pharmaceuticals Co., Ltd., Tokyo 106-6020, Japan.
  • 3 Neopharma Japan Co., Ltd., Tokyo 102-0071, Japan.
Abstract

Photodynamic therapy (PDT) is a clinically approved, minimally invasive treatment for malignant tumors. Protoporphyrin IX (PpIX), derived from 5-aminolevulinic acid (5-ALA) as the prodrug, is one of the photosensitizers used in PDT. Recently, we reported a significant difference in response to 5-ALA-mediated PDT treatment in two canine primary lung adenocarcinoma cell lines (sensitive to PDT: HDC cells, resistant to PDT: LuBi cells). This study aimed to examine the difference in cytotoxicity of 5-ALA-mediated PDT in these cells. Although intracellular PpIX levels before irradiation were similar between HDC and LuBi cells, the percentage of ROS-positive cells and apoptotic cells in LuBi cells treated with 5-ALA-mediated PDT was significantly lower than that in HDC cells treated with 5-ALA-mediated PDT. A high dosage of the NO donor, DETA NONOate, significantly increased the cytotoxicity of 5-ALA-mediated PDT against LuBi cells. These results suggest that the sensitivity of 5-ALA-mediated PDT might be correlated with NO.

Keywords

canine carcinoma; lung adenocarcinoma; photodynamic therapy; tumor.

Figures
Products